atl1102 in the Box seat re DMD. Sarepta fails ., page-2

Reference Stockmaster:
Sarepta could earn $800 mill for 2022
But they have no approved drugs for DMD
Atl1102 looks like a winner.
The non ambulant market is bigger than the ambulant..
Hold tight guys .. Sarepta will come knocking..$$$

Analysts have a consensus estimate of $197.38 million for the company’s revenue for the quarter, with a low and high estimate of $182 million and $204 million respectively
. The average forecast suggests up to a 36.00% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue for 2021 to grow to $691.36 million, representing a 28.00% jump on that reported in the last financial year
.Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that SRPT is a 50% Sell
. On the other hand, the stock is on average a Hold as suggested by medium term indicators while long term indicators are putting the stock in Hold category.